Literature DB >> 19862826

Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.

Hideki Nakasone1, Yoshinobu Kanda, Tomoki Ueda, Kenji Matsumoto, Naomi Shimizu, Jiro Minami, Rika Sakai, Maki Hagihara, Akira Yokota, Kumi Oshima, Yuiko Tsukada, Takayoshi Tachibana, Chiaki Nakaseko, Shin Fujisawa, Shingo Yano, Hiroyuki Fujita, Satoshi Takahashi, Heiwa Kanamori, Shinichiro Okamoto.   

Abstract

The combination of cyclophosphamide and granulocyte-colony stimulating factor (G-CSF) has widely been used to mobilize hematopoietic stem cells (HSCs) for autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Recently, however, alternative approaches such as G-CSF alone or etoposide followed by G-CSF have been investigated. We, therefore, retrospectively analyzed the effects of these mobilization methods on collection yield and disease outcome in ASCT for MM. We reviewed 146 MM patients from whom we intended to collect stem cells. For mobilization, 67, 58, and 21 patients received cyclophosphamide and G-CSF, etoposide and G-CSF, and G-CSF alone (including nonmyelosuppressive chemotherapy followed by G-CSF), respectively. Among them, 136 achieved the target number of HSCs (at least 2 x 10(6)/kg). Lower creatinine and higher albumin levels at diagnosis were significantly associated with successful yield. A lower number of infused HSCs, use of the etoposide for mobilization and high ISS were associated with delayed hematopoietic recovery. The mobilization methods did not significantly affect either the successful collection of more than 2 x 10(6) CD34-positive cells/kg or PFS after ASCT. G-CSF alone was sufficient for stem cell mobilization for a single ASCT. The optimal approach to collect HSCs in MM remains to be elucidated. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19862826     DOI: 10.1002/ajh.21552

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

Review 1.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

2.  Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Authors:  Sascha A Tuchman; Wendi A Bacon; Li-Wen Huang; Gwynn Long; David Rizzieri; Mitchell Horwitz; John P Chute; Keith Sullivan; Ashley Morris Engemann; Amanda Yopp; Zhiguo Li; Kelly Corbet; Nelson Chao; Cristina Gasparetto
Journal:  J Clin Apher       Date:  2014-10-08       Impact factor: 2.821

3.  Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.

Authors:  Akira Tanimura; Risen Hirai; Miki Nakamura; Masataka Takeshita; Shotaro Hagiwara; Akiyoshi Miwa
Journal:  Int J Hematol       Date:  2018-01-31       Impact factor: 2.490

4.  Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

Authors:  Hikmettullah Batgi; Semih Başcı; Mehmet Sinan Dal; Merih Kızıl Çakar; Bahar Uncu Ulu; Tuğçe Nur Yiğenoğlu; Nurgül Özcan; Ali Kılınç; Alparslan Merdin; Jale Yıldız; Mehmet Bakırtaş; Derya Şahin; Tahir Darçın; Dicle İskender; Nuran Ahü Baysal; Fevzi Altuntaş
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

5.  Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.

Authors:  Vânia Tietsche de Moraes Hungria; Edvan de Queiroz Crusoe; Adriana Alvarez Quero; Manuella Sampaio; Angelo Maiolino; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2013

6.  Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.

Authors:  Liwen Wang; Hongxian Xiang; Yuhan Yan; Zuqun Deng; Hui Li; Xin Li; Jin Liu
Journal:  Ann Hematol       Date:  2021-01-06       Impact factor: 3.673

Review 7.  Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

Authors:  Louis M Pelus; Sherif S Farag
Journal:  Stem Cells Cloning       Date:  2011-02-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.